Galectin Therapeutics (GALT) Other Non Operating Income (2010 - 2026)
Galectin Therapeutics' quarterly Other Non Operating Income came in at $983000.0 in Q1 2026, up 4032.0% year-on-year from $23789.9 in Q1 2025, and up 544.8% quarter-over-quarter from -$221000.0 in Q4 2025.
Galectin Therapeutics has reported Other Non Operating Income for 9 years, with the latest figure at $983000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 4032.0% year-over-year to $983000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 277.18% YoY), and the FY2025 full-year result was -$3.5 million, down 703.4% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $983000.0, up from -$221000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $3.6 million in Q3 2023, with the low at -$2.2 million in Q3 2025.
- Average Other Non Operating Income over 5 years is $105866.7, with a median of -$25000.0 recorded in 2025.
- Year-over-year, Other Non Operating Income tumbled 1105.5% in 2025 and soared 4032.0% in 2026.
- Tracing GALT's Other Non Operating Income over 5 years: stood at -$280000.0 in 2022, then surged by 1392.5% to $3.6 million in 2023, then sank by 41.92% to $2.1 million in 2024, then slumped by 110.51% to -$221000.0 in 2025, then surged by 544.8% to $983000.0 in 2026.
- The last three Other Non Operating Income figures came in at $983000.0 (Q1 2026), -$221000.0 (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 983,000.00 |
| Dec 31, 2025 | -221,000.00 |
| Sep 30, 2025 | -2.21 Mn |
| Jun 30, 2025 | -1.10 Mn |
| Mar 31, 2025 | -25,000.00 |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | -753,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | -869,000.00 |
| Dec 31, 2023 | -4.05 Mn |
| Sep 30, 2023 | -489,000.00 |
| Jun 30, 2023 | 489,000.00 |
| Mar 31, 2023 | -769,000.00 |
| Dec 31, 2022 | -280,000.00 |
| Sep 30, 2022 | -224,000.00 |
| Jun 30, 2022 | 275,000.00 |
| Mar 31, 2022 | 229,000.00 |
| Dec 31, 2021 | 170,000.00 |
| Sep 30, 2021 | -18,000.00 |
| Jun 30, 2021 | -172,000.00 |
| Sep 30, 2012 | 200,000.00 |
| Dec 31, 2011 | 1.05 Mn |
| Jun 30, 2011 | -140,000.00 |
| Mar 31, 2011 | -384,000.00 |
| Dec 31, 2010 | 1.80 Mn |
| Sep 30, 2010 | 100,000.00 |
| Jun 30, 2010 | -305,000.00 |